A previous study showed that prolonging afatinib therapy in EGFR-mutated NSCLC by adding bevacizumab led to a positive acquired T790M mutation conversion, and the results in the same study suggested that prolonging afatinib therapy may induce the clonal selection of acquired T790M-mutated NSCLC cells (27). Here, EGFR is linked to non-small cell lung carcinoma.